Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss - Seite 2

Nawal Ouzren, Sensorion’s Chief Executive Officer, said: "I am excited to share these new positive findings from our Phase 2a clinical trial on SENS-401, which demonstrate the clinically meaningful effect of our small molecule in preserving the residual hearing of patients undergoing cochlear implantation. Reaching this key secondary endpoint strongly supports SENS-401’s ambition to potentially improve the quality of hearing of patients undergoing such surgery. We plan to communicate the full final data later in Q3 2024. We remain entirely focused on developing our hearing care franchise by developing our portfolio of very innovative therapies to address important hearing loss disorders, a significant global unmet need.”

Géraldine Honnet, M.D., Sensorion’s Chief Medical Officer, said: "The new results obtained for SENS-401 show the efficacy of the drug candidate in preserving residual hearing. I am delighted to report the difference in hearing loss between the treated group and the control group and the maintenance of this effect up to 14 weeks post implantation with 25 dB loss at 500 Hz in the treated group compared to 35 dB loss in the control group. I would like to extend my gratitude to every patient, partner and investigator who participated in this study.”

The Company plans on communicating the full final data later in Q3 2024.

About SENS-401

SENS-401 (Arazasetron), Sensorion’s clinical stage lead drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion currently develops SENS-401 in a Phase 2a for the prevention of residual hearing loss in patients scheduled for cochlear implantation and in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the U.S. for the prevention of platinum-induced ototoxicity in pediatric population.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.